合并亚临床甲减的2型糖尿病患者临床及生化特征分析

The Clinical and Biochemical Features of Patients with Type 2 Diabetes Complicated by Subclinical Hypothyroidism

目的探讨亚临床甲状腺功能减退症(SCH)对2型糖尿病(T2DM)患者血糖控制及代谢指标的影响.方法纳入住院的T2DM患者973例,测量身高、体重、血压,计算BMI;完善HbA1c、TC、TG、HDL-C、LDL-C、尿酸及甲状腺功能(TSH、TT4、TT3、FT4、FT3)检查.纳入的T2DM患者中筛查出合并SCH者148例(SCH组),在甲状腺功能正常的T2DM患者中选取性别、年龄及糖尿病病程相匹配的152例作为对照组(NSCH组).结果 (1)T2DM合并SCH的患病率为15.3%;(2)与NSCH组相比,SCH组超重/肥胖者比例(54.1%vs 35.5%,P<0.01)及高血压者比例(64.9%vs 52%,P<0.05)显著增高.两组间在HbA1c达标、高TC血症、高TG血症、低HDL血症、高LDL血症及高尿酸血症者比例无显著差异.结论 SCH对T2DM患者的血压、体重指数等代谢指标可能存在不良影响.

Objective To investigate the effects of subclinical hypothyroidism （SCH） on blood glucose and metabolic parameters in type 2 diabetes （T2DM） . Methods A total of 973 T2DM patients were recruited, and the clinical data, biochemical and thyroid function parameters were measured. One hundred and forty eight T2DM patients were diagnosed as SCH （SCH group） and 152 euthyroid patients were selected as control group （NSCH group） . Results （1） The prevalence of SCH in type 2 diabetes was 15.3% （148/973） （2） Compared with the NSCH group, the prevalence of overweight/obesity was significantly higher in SCH group （54.1% vs 35.5%, P 〈 0.01） as well as hypertension （64.9% vs 52%, P 〈 0.05） . There was no significant difference in HbAlc control and prevalence of dyslipidemia and hyperuricemia between two groups. Conclusion SCH may have some